Salikova V V, Nonikov V E, Belousov Iu B
Ter Arkh. 1993;65(8):41-4.
A randomized trial of long-acting theophylline drugs theopek taken twice daily and euphilong taken in a single daily dose has been performed in 59 elderly patients suffering from bronchial asthma, chronic obstructive bronchitis. The drugs' doses were adjusted to blood theophylline concentrations, clinical response, side effects. Theophylline concentrations were maintained in therapeutic doses. A 24 hour monitoring showed the highest concentrations of theophylline to be achieved at night and early in the morning in the group of patients on euphilong. A clinical response with improvement of external respiration became evident by the treatment day 5 and persisted by day 90. Side effects were not severe. Both the drugs are recommended for long-term treatment. When euphilong was given in a single evening dose, its efficacy was superior at night and early in the morning making the drug preferable in patients with night asthma.
针对59名患有支气管哮喘、慢性阻塞性支气管炎的老年患者,开展了一项长效茶碱类药物的随机试验,其中一种药物是每日服用两次的Theopek,另一种是每日服用一次的Eupophylline。根据血药浓度、临床反应和副作用来调整药物剂量,使茶碱浓度维持在治疗剂量水平。24小时监测显示,服用Eupophylline的患者组在夜间和清晨时血药浓度最高。到治疗第5天时,患者的外部呼吸状况明显改善,且这种改善持续到第90天。副作用并不严重。两种药物均推荐用于长期治疗。当Eupophylline在每晚单次给药时,其在夜间和清晨的疗效更佳,因此更适合用于患有夜间哮喘的患者。